Last reviewed · How we verify
SCH 697243
SCH 697243 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity.
SCH 697243 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity. Used for Non-small cell lung cancer, Melanoma.
At a glance
| Generic name | SCH 697243 |
|---|---|
| Also known as | Phleum pratense extract |
| Sponsor | ALK-Abelló A/S |
| Drug class | TLR9 agonist |
| Target | TLR9 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TLR9 agonists work by binding to toll-like receptor 9 on immune cells, triggering pattern recognition and downstream signaling that promotes dendritic cell activation and T-cell responses. This mechanism is designed to enhance the body's natural anti-tumor immune response, particularly in combination with other immunotherapies or as a monotherapy in certain cancers.
Approved indications
- Non-small cell lung cancer
- Melanoma
Common side effects
- Injection site reactions
- Flu-like symptoms
- Fatigue
Key clinical trials
- A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067) (PHASE3)
- Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) (PHASE4)
- Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) (PHASE3)
- Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |